Michael Hayden - Aurinia Pharmaceuticals Director
| AUPH Stock | USD 5.09 0.04 0.79% |
Director
Dr. Michael R. Hayden, Ph.D., is Director of the company. He was recently named one of the 50 Canadians born in the 20th century who have changed the world. He is the cofounder of three biotechnology companies NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corporationration Dr. Hayden sits on different boards including Xenon Pharmaceuticals and Lycera. Author of over 860 peerreviewed publications and invited submissions, Dr. Hayden has focused his research primarily on genetic diseases, including genetics of diabetes, lipoprotein disorders, Huntington disease, predictive and personalized medicine. Dr. Hayden was inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice 100 of the Most Inspiring People awarded an Honorary Doctor of Science by the University of Gottingen the Luminary award by the Personalized Medicine World Conference and the Diamond Jubilee Medal, on behalf of HRH Queen Elisabeth II, in recognition of his significant contributions and achievements. Dr. Hayden has also been awarded the Order of Canada, and the Order of British Columbia . He was named Canada Health Researcher of the Year by CIHR in 2008, and he received the Prix Galien in 2007, which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research. since 2018.
| Age | 66 |
| Tenure | 6 years |
| Address | 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6 |
| Phone | 250 744 2487 |
| Web | https://www.auriniapharma.com |
Aurinia Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1052) % which means that it has lost $0.1052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1992) %, meaning that it created substantial loss on money invested by shareholders. Aurinia Pharmaceuticals' management efficiency ratios could be used to measure how well Aurinia Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Aurinia Pharmaceuticals' Total Current Assets are increasing as compared to previous years. The Aurinia Pharmaceuticals' current Intangible Assets is estimated to increase to about 7 M, while Net Current Asset Value is forecasted to increase to (8.5 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dennis Ausiello | Seres Therapeutics | 72 | |
| Mark Schoenebaum | TG Therapeutics | 45 | |
| Charles Rowland | Viking Therapeutics | 59 | |
| Maria Freire | Exelixis | 63 | |
| David Berry | Seres Therapeutics | 37 | |
| Gil Price | Sarepta Therapeutics | 58 | |
| Mark Coleman | Axsome Therapeutics | 49 | |
| Adam Koppel | PTC Therapeutics | 45 | |
| Kathy Rouan | Viking Therapeutics | 56 | |
| Richard Kender | Seres Therapeutics | 62 | |
| Peter Hutt | Seres Therapeutics | 80 | |
| Jack Wyszomierski | Exelixis | 62 | |
| Richard Barry | Sarepta Therapeutics | 59 | |
| JeanPaul Kress | Sarepta Therapeutics | 49 | |
| Vincent Marchesi | Exelixis | 82 | |
| Matthew Singleton | Viking Therapeutics | 65 | |
| MD FACP | Hepion Pharmaceuticals | N/A | |
| Robert Wilson | Madrigal Pharmaceuticals | 75 | |
| Krishnan Nandabalan | BioXcel Therapeutics | 61 | |
| Jenna Bosco | TG Therapeutics | N/A | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.11 |
Aurinia Pharmaceuticals Leadership Team
Elected by the shareholders, the Aurinia Pharmaceuticals' board of directors comprises two types of representatives: Aurinia Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aurinia. The board's role is to monitor Aurinia Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aurinia Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aurinia Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Celia Economides, Associate Vice President Corporate Communications & Patient Advocacy | ||
| Lorin Randall, Director | ||
| Neil Solomons, Chief Marketing Officer | ||
| Joseph CPA, Chief Officer | ||
| Michael Martin, Chief Officer | ||
| George Milne, Director | ||
| Benjamin Rovinski, Independent Director | ||
| Michael Hayden, Director | ||
| Richard Glickman, Executive Chairman of the Board | ||
| Stephen Zaruby, CEO and President Director and Member of Corporate Governance Committee | ||
| MD DSc, Executive Development | ||
| Robert Huizinga, Vice President - Clinical Affairs | ||
| Lawrence Mandt, VP of Regulatory Affairs and Quality | ||
| DeDe Sheel, Vice Relation | ||
| James Harrell, Head Relations | ||
| Chris Hays, VP Marketing | ||
| Charles Rowland, Director | ||
| Joseph Hagan, Director | ||
| Peter MBA, CEO President | ||
| Andrea Christopher, Head Relations | ||
| Fran Lynch, Vice Sales | ||
| Peter Greenleaf, CEO, Director | ||
| Daniel Billen, Director | ||
| Matthew MBA, Executive Strategy | ||
| Dennis Bourgeault, CFO, Corporate Secretary | ||
| Sue Evans, Senior Affairs | ||
| Scott Habig, Chief Officer | ||
| Stephen Robertson, General VP |
Aurinia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aurinia Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | 477.56 M | ||||
| Shares Outstanding | 144.62 M | ||||
| Shares Owned By Insiders | 7.44 % | ||||
| Shares Owned By Institutions | 38.53 % | ||||
| Number Of Shares Shorted | 12.24 M | ||||
| Price To Earning | (4.83) X |
Aurinia Pharmaceuticals Investors Sentiment
The influence of Aurinia Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Aurinia. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Aurinia Pharmaceuticals' public news can be used to forecast risks associated with an investment in Aurinia. The trend in average sentiment can be used to explain how an investor holding Aurinia can time the market purely based on public headlines and social activities around Aurinia Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Aurinia Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Aurinia Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Aurinia Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Aurinia Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aurinia Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aurinia Pharmaceuticals' short interest history, or implied volatility extrapolated from Aurinia Pharmaceuticals options trading.
Pair Trading with Aurinia Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aurinia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aurinia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Aurinia Stock
| 0.91 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.87 | CNTA | Centessa Pharmaceuticals Downward Rally | PairCorr |
| 0.85 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
| 0.84 | OPT | Opthea | PairCorr |
| 0.8 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Aurinia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aurinia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aurinia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aurinia Pharmaceuticals to buy it.
The correlation of Aurinia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aurinia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aurinia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aurinia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Aurinia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.225 | Quarterly Revenue Growth 0.586 | Return On Assets (0.11) | Return On Equity (0.20) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.